Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
Tóm tắt
This document updates and expands the initial Infectious Diseases Society of America (IDSA) Fever and Neutropenia Guideline that was published in 1997 and first updated in 2002. It is intended as a guide for the use of antimicrobial agents in managing patients with cancer who experience chemotherapy-induced fever and neutropenia.
Recent advances in antimicrobial drug development and technology, clinical trial results, and extensive clinical experience have informed the approaches and recommendations herein. Because the previous iteration of this guideline in 2002, we have a developed a clearer definition of which populations of patients with cancer may benefit most from antibiotic, antifungal, and antiviral prophylaxis. Furthermore, categorizing neutropenic patients as being at high risk or low risk for infection according to presenting signs and symptoms, underlying cancer, type of therapy, and medical comorbidities has become essential to the treatment algorithm. Risk stratification is a recommended starting point for managing patients with fever and neutropenia. In addition, earlier detection of invasive fungal infections has led to debate regarding optimal use of empirical or preemptive antifungal therapy, although algorithms are still evolving.
What has not changed is the indication for immediate empirical antibiotic therapy. It remains true that all patients who present with fever and neutropenia should be treated swiftly and broadly with antibiotics to treat both gram-positive and gram-negative pathogens.
Finally, we note that all Panel members are from institutions in the United States or Canada; thus, these guidelines were developed in the context of North American practices. Some recommendations may not be as applicable outside of North America, in areas where differences in available antibiotics, in the predominant pathogens, and/or in health care–associated economic conditions exist. Regardless of venue, clinical vigilance and immediate treatment are the universal keys to managing neutropenic patients with fever and/or infection.
Từ khóa
Tài liệu tham khảo
Hughes, 2002, 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer, Clin Infect Dis, 34, 730, 10.1086/339215
Klastersky, 2004, Management of fever in neutropenic patients with different risks of complications, Clin Infect Dis, 39, S32, 10.1086/383050
Bodey, 1966, Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia, Ann Intern Med, 64, 328, 10.7326/0003-4819-64-2-328
Rosenberg, 2006, The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy, Blood, 107, 4628, 10.1182/blood-2005-11-4370
Ramphal, 2004, Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens, Clin Infect Dis, 39, S25, 10.1086/383048
Zinner, 1999, Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria, Clin Infect Dis, 29, 490, 10.1086/598620
Wisplinghoff, 2003, Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States, Clin Infect Dis, 36, 1103, 10.1086/374339
Cattaneo, 2008, Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution, J Antimicrob Chemother, 61, 721, 10.1093/jac/dkm514
Oliveira, 2007, Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients, Bone Marrow Transplant, 39, 775, 10.1038/sj.bmt.1705677
Chen, 2004, Trends and antimicrobial resistance of pathogens causing bloodstream infections among febrile neutropenic adults with hematological malignancy, J Formos Med Assoc, 103, 526
Johnson, 1990, Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy, J Infect Dis, 162, 981, 10.1093/infdis/162.4.981
Johnson, 1992, A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients, J Antimicrob Chemother, 30, 203, 10.1093/jac/30.2.203
Aubron, 2005, Nosocomial spread of Pseudomonas aeruginosa isolates expressing the metallo-beta-lactamase VIM-2 in a hematology unit of a French hospital, Microb Drug Resist, 11, 254, 10.1089/mdr.2005.11.254
Morris, 2008, Emergence of MRSA in positive blood cultures from patients with febrile neutropenia-a cause for concern, Support Care Cancer, 16, 1085, 10.1007/s00520-007-0398-5
Weinstock, 2007, Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant, Biol Blood Marrow Transplant, 13, 615, 10.1016/j.bbmt.2007.01.078
Carratala, 1998, Bacteremic pneumonia in and neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome, Arch Intern Med, 158, 868, 10.1001/archinte.158.8.868
Zuckermann, 2008, Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes, Ann Hematol, 87, 139, 10.1007/s00277-007-0390-7
Field, 1990, Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines, Clinical practice guidelines: directions for a new program, 8, 10.17226/1626
1979, Canadian Task Force on the Periodic Health Examination, Can Med Assoc J, 121, 1193
Gardembas-Pain, 1991, Home treatment of febrile neutropenia: an empirical oral antibiotic regimen, Ann Oncol, 2, 485, 10.1093/oxfordjournals.annonc.a057996
Malik, 1992, Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients, Lancet, 339, 1092, 10.1016/0140-6736(92)90674-R
Aquino, 1997, Early discharge of low-risk febrile neutropenic children and adolescents with cancer, Clin Infect Dis, 25, 74, 10.1086/514512
Freifeld, 1999, A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy, N Engl J Med, 341, 305, 10.1056/NEJM199907293410501
Hidalgo, 1999, Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial, Cancer, 85, 213, 10.1002/(SICI)1097-0142(19990101)85:1<213::AID-CNCR29>3.0.CO;2-D
Jones, 1994, Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition, J Pediatr, 124, 703, 10.1016/S0022-3476(05)81358-7
Kern, 1999, Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer, N Engl J Med, 341, 312, 10.1056/NEJM199907293410502
Klaassen, 2000, “Low-risk” prediction rule for pediatric oncology patients presenting with fever and neutropenia, J Clin Oncol, 18, 1012, 10.1200/JCO.2000.18.5.1012
Malik, 1995, Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial, Am J Med, 98, 224, 10.1016/S0002-9343(99)80367-2
Mullen, 1999, Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients, Cancer, 86, 126, 10.1002/(SICI)1097-0142(19990701)86:1<126::AID-CNCR18>3.0.CO;2-1
Paganini, 2000, Oral administration of cefixime to lower risk febrile neutropenic children with cancer, Cancer, 88, 2848, 10.1002/1097-0142(20000615)88:12<2848::AID-CNCR27>3.0.CO;2-2
Rackoff, 1996, Predicting the risk of bacteremia in childen with fever and neutropenia, J Clin Oncol, 14, 919, 10.1200/JCO.1996.14.3.919
Rolston, 1999, New trends in patient management: risk-based therapy for febrile patients with neutropenia, Clin Infect Dis, 29, 515, 10.1086/598624
Shenep, 2001, Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer, Clin Infect Dis, 32, 36, 10.1086/317552
Talcott, 1992, Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule, J Clin Oncol, 10, 316, 10.1200/JCO.1992.10.2.316
Elting, 2008, Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia, J Clin Oncol, 26, 606, 10.1200/JCO.2007.13.8222
Rolston, 2006, Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated risk-prediction rules, Cancer, 106, 2489, 10.1002/cncr.21908
Rubenstein, 1993, Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer, Cancer, 71, 3640, 10.1002/1097-0142(19930601)71:11<3640::AID-CNCR2820711128>3.0.CO;2-H
Velasco, 1995, Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients, Am J Clin Oncol, 18, 429, 10.1097/00000421-199510000-00014
Petrilli, 2000, Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial, Med Pediatr Oncol, 34, 87, 10.1002/(SICI)1096-911X(200002)34:2<87::AID-MPO2>3.0.CO;2-F
Innes, 2003, Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study, Br J Cancer, 89, 43, 10.1038/sj.bjc.6600993
Kamana, 2005, Bacterial infections in low-risk, febrile neutropenic patients, Cancer, 104, 423, 10.1002/cncr.21144
Klastersky, 2006, Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications, J Clin Oncol, 24, 4129, 10.1200/JCO.2005.03.9909
Klastersky, 2000, The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients, J Clin Oncol, 18, 3038, 10.1200/JCO.2000.18.16.3038
Klastersky, 2007, Bacteraemia in febrile neutropenic cancer patients, Int J Antimicrob Agents, 30, S51, 10.1016/j.ijantimicag.2007.06.012
Kern, 2006, Risk assessment and treatment of low-risk patients with febrile neutropenia, Clin Infect Dis, 42, 533, 10.1086/499352
Talcott, 1988, The medical course of cancer patients with fever neutropenia. Clinical identification of a low-risk subgroup at presentation, Arch Intern Med, 148, 2561, 10.1001/archinte.1988.00380120031007
Mermel, 1993, Detection of bacteremia in adults: consequences of culturing an inadequate volume of blood, Ann Intern Med, 119, 270, 10.7326/0003-4819-119-4-199308150-00003
Gaur, 2005, Diagnosis of catheter-related bloodstream infections among pediatric oncology patients lacking a peripheral culture, using differential time to detection, Pediatr Infect Dis J, 24, 445, 10.1097/01.inf.0000160950.83583.7f
Lee, 2007, Detection of bloodstream infections in adults: how many blood cultures are needed?, J Clin Microbiol, 45, 3546, 10.1128/JCM.01555-07
Cockerill, 2004, Optimal testing parameters for blood cultures, Clin Infect Dis, 38, 1724, 10.1086/421087
DesJardin, 1999, Clinical utility of blood cultures drawn from indwelling central venous catheters in hospitalized patients with cancer, Ann Intern Med, 131, 641, 10.7326/0003-4819-131-9-199911020-00002
Weinstein, 1996, Current blood culture methods and systems: clinical concepts, technology, and interpretation of results, Clin Infect Dis, 23, 40, 10.1093/clinids/23.1.40
Adamkiewicz, 1999, Peripheral vs. central blood cultures in patients admitted to a pediatric oncology ward, Pediatr Infect Dis J, 18, 556, 10.1097/00006454-199906000-00018
Allen, 1986, The value of skin biopsies in febrile, neutropenic, immunocompromised children, Am J Dis Child, 140, 459
von Lilienfeld-Toal, 2004, Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein, Eur J Clin Microbiol Infect Dis, 23, 539
Persson, 2005, Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia, Eur J Haematol, 74, 297, 10.1111/j.1600-0609.2004.00387.x
von Lilienfeld-Toal, 2006, Change of procalcitonin predicts clinical outcome of febrile episodes in patients with hematological malignancies, Support Care Cancer, 14, 1241, 10.1007/s00520-006-0081-2
Pizzo, 1982, Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia, Am J Med, 72, 101, 10.1016/0002-9343(82)90594-0
Schimpff, 1986, Empiric antibiotic therapy for granulocytopenic cancer patients, Am J Med, 80, 13
Antoniadou, 2007, Fever of unknown origin in febrile leukopenia, Infect Dis Clin North Am, 21, 1055, 10.1016/j.idc.2007.08.008
Spanik, 1999, Bacteremia due to multiresistant gram-negative bacilli in neutropenic cancer patients: a case-controlled study, J Infect Chemother, 5, 180, 10.1007/s101560050031
Falcone, 2004, Methicillin-resistant staphylococcal bacteremia in patients with hematologic malignancies: clinical and microbiological retrospective comparative analysis of S. haemolyticus, S. epidermidis and S. aureus, J Chemother, 16, 540, 10.1179/joc.2004.16.6.540
Bow, 2006, A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies, Clin Infect Dis, 43, 447, 10.1086/505393
Glasmacher, 2005, An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients, Clin Microbiol Infect, 11, 17, 10.1111/j.1469-0691.2005.01239.x
Cherif, 2004, A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies, Scand J Infect Dis, 36, 593, 10.1080/00365540410017590
Escalante, 2004, Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients, Support Care Cancer, 12, 657
Raad, 2003, Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime, Cancer, 98, 1039, 10.1002/cncr.11613
Wang, 1999, A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients, Chemotherapy, 45, 370, 10.1159/000007228
Biron, 1998, Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer), J Antimicrob Chemother, 42, 511, 10.1093/jac/42.4.511
Freifeld, 1995, Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem, J Clin Oncol, 13, 165, 10.1200/JCO.1995.13.1.165
Mustafa, 2001, Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia, Pediatr Infect Dis J, 20, 362, 10.1097/00006454-200103000-00036
Corapcioglu, 2006, Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison, Pediatr Hematol Oncol, 23, 177, 10.1080/08880010500506370
Oguz, 2006, Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors, Pediatr Hematol Oncol, 23, 245, 10.1080/08880010500506867
Ramphal, 1999, Is monotherapy for febrile neutropenia still a viable alternative?, Clin Infect Dis, 29, 508, 10.1086/598623
Raad, 1998, How should imipenem-cilastatin be used in the treatment of fever and infection in neutropenic cancer patients?, Cancer, 82, 2449, 10.1002/(SICI)1097-0142(19980615)82:12<2449::AID-CNCR20>3.0.CO;2-O
Ramphal, 1996, Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient, Am J Med, 100, 83S, 10.1016/S0002-9343(96)00113-1
Feld, 2000, Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial, J Clin Oncol, 18, 3690, 10.1200/JCO.2000.18.21.3690
Owens, 2000, Reduction in vancomycin consumption in patients with fever and neutropenia, Clin Infect Dis, 31, 291
Vandercam, 2000, Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients, Ann Hematol, 79, 152, 10.1007/s002770050571
Rubinstein, 1995, Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Antibiotic Study Group, Clin Infect Dis, 20, 1217, 10.1093/clinids/20.5.1217
Winston, 1991, Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone, Ann Intern Med, 115, 849, 10.7326/0003-4819-115-11-849
De Pauw, 1994, Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group, Ann Intern Med, 120, 834, 10.7326/0003-4819-120-10-199405150-00004
Pizzo, 1986, A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia, N Engl J Med, 315, 552, 10.1056/NEJM198608283150905
Lindblad, 1998, Empiric monotherapy for febrile neutropenia–a randomized study comparing meropenem with ceftazidime, Scand J Infect Dis, 30, 237, 10.1080/00365549850160864
Behre, 1998, Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients, Ann Hematol, 76, 73, 10.1007/s002770050366
Bohme, 1998, Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study, Eur J Med Res, 3, 324
Del Favero, 2001, A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia, Clin Infect Dis, 33, 1295, 10.1086/322646
Engervall, 1999, Cefepime as empirical monotherapy in febrile patients with hematological malignancies and neutropenia: a randomized, single-center phase II trial, J Chemother, 11, 278, 10.1179/joc.1999.11.4.278
Ozyilkan, 1999, Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients, Korean J Intern Med, 14, 15, 10.3904/kjim.1999.14.2.15
Akova, 1999, Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey, Int J Antimicrob Agents, 13, 15, 10.1016/S0924-8579(99)00096-5
Yamamura, 1997, Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients, Antimicrob Agents Chemother, 41, 1704, 10.1128/AAC.41.8.1704
Cometta, 1996, Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program, Antimicrob Agents Chemother, 40, 1108, 10.1128/AAC.40.5.1108
Paul, 2003, Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia, Cochrane Database Syst Rev, 10.1002/14651858.CD003038
Paterson, 2001, Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, J Clin Microbiol, 39, 2206, 10.1128/JCM.39.6.2206-2212.2001
Kang, 2004, Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy, Antimicrob Agents Chemother, 48, 4574, 10.1128/AAC.48.12.4574-4581.2004
Fritsche, 2003, Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001–2002), Diagn Microbiol Infect Dis, 47, 435, 10.1016/S0732-8893(03)00114-7
Yahav, 2007, Efficacy and safety of cefepime: a systematic review and meta-analysis, Lancet Infect Dis, 7, 338, 10.1016/S1473-3099(07)70109-3
Gomez, 2009, Mortality associated with cefepime therapy among neutropenic patients, Clin Infect Dis, 49, 987, 10.1086/605535
Chemaly, 2009, Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution, Medicine (Baltimore), 88, 211, 10.1097/MD.0b013e3181af01fc
No authors listed, 1991, Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group, J Infect Dis, 163, 951, 10.1093/infdis/163.5.951
Paul, 2005, Empirical antibiotics against gram-positive infections for febrile neutropenia: systematic review and meta-zanalysis of randomized controlled trials, J Antimicrob Chemother, 55, 436, 10.1093/jac/dki028
Elting, 1997, Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials, Clin Infect Dis, 25, 247, 10.1086/514550
Razonable, 2002, Bacteremia due to viridans group Streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis, Clin Infect Dis, 34, 1469, 10.1086/340352
Nucci, 2001, Application of the IDSA guidelines for the use of antimicrobial agents in neutropenic patients: impact on reducing the use of glycopeptides, Infect Control Hosp Epidemiol, 22, 651, 10.1086/501839
Mehta, 2006, Emergence of linezolid-resistant enterococci in a neutropenic patient, J Hosp Infect, 62, 125, 10.1016/j.jhin.2005.05.008
Verma, 2007, Gut overgrowth of vancomycin-resistant enterococci (VRE) results in linezolid-resistant mutation in a child with severe congenital neutropenia: a case report, J Pediatr Hematol Oncol, 29, 557, 10.1097/MPH.0b013e3180f61b81
Aksoy, 2008, New antimicrobial agents for the treatment of gram-positive bacterial infections, Clin Microbiol Infect, 14, 411, 10.1111/j.1469-0691.2007.01933.x
Rice, 2006, Antimicrobial resistance in gram-positive bacteria, Am J Infect Control, 34, S11, 10.1016/j.ajic.2006.05.220
Whitener, 2004, Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure, Clin Infect Dis, 38, 1049, 10.1086/382357
Cunha, 2006, Antimicrobial therapy of multidrug-resistant Strptococcus pneumoniae, vancomycin-resistant enterococci, and methicillin-resistant Staphylococcus aureus, Med Clin North Am, 90, 1165, 10.1016/j.mcna.2006.07.007
Bruckner, 2006, Viridans group streptococcal infections among children with cancer and the importance of emerging antibiotic resistance, Semin Pediatr Infect Dis, 17, 153, 10.1053/j.spid.2006.06.008
Elting, 1992, Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors, Clin Infect Dis, 14, 1201, 10.1093/clinids/14.6.1201
Gruson, 1998, Severe infection caused by Stomatococcus mucilaginosus in a neutropenic patient: case report and review of the literature, Hematol Cell Ther, 40, 167
Kumashi, 2005, e bacteremia in patients with cancer: disease characteristics and outcomes in the era of escalating drug resistance (1998-2002), Medicine (Baltimore), 84, 303, 10.1097/01.md.0000180045.26909.29
DiazGranados, 2005, Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection, J Infect Dis, 191, 588, 10.1086/427512
Koc, 1998, Vancomycin-resistant enterococcal infections in bone marrow transplant recipients, Bone Marrow Transplant, 22, 207, 10.1038/sj.bmt.1701303
Vergis, 2001, Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study, Ann Intern Med, 135, 484, 10.7326/0003-4819-135-7-200110020-00007
Johnson, 1990, High dose intravenous ciprofloxacin in febrile neutropenic patients, J Antimicrob Chemother, 26, 101, 10.1093/jac/26.suppl_F.101
Winston, 2001, Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients, Clin Infect Dis, 32, 381, 10.1086/318500
Meunier, 1991, Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group, Antimicrob Agents Chemother, 35, 873, 10.1128/AAC.35.5.873
Anaissie, 1988, Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients, Am J Med, 84, 581, 10.1016/0002-9343(88)90140-4
Bodey, 1990, Beta-lactam regimens for the febrile neutropenic patient, Cancer, 65, 9, 10.1002/1097-0142(19900101)65:1<9::AID-CNCR2820650105>3.0.CO;2-C
Freifeld, 2008, Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA, Support Care Cancer, 16, 181, 10.1007/s00520-007-0308-x
Cornely, 2004, Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia, Int J Hematol, 79, 74, 10.1007/BF02983537
Burgess, 2003, In vitro evaluation of the activity of two doses of levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa, Diagn Microbiol Infect Dis, 46, 131, 10.1016/S0732-8893(03)00036-1
Garrison, 2006, Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa, Diagn Microbiol Infect Dis, 54, 51, 10.1016/j.diagmicrobio.2005.08.010
Cometta, 2003, Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy, Clin Infect Dis, 37, 382, 10.1086/376637
Gil, 2007, Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome, Infection, 35, 421, 10.1007/s15010-007-6350-2
Wade, 2004, Vancomycin does not benefit persistently febrile neutropenic people with cancer, Cancer Treat Rev, 30, 119, 10.1016/j.ctrv.2003.11.008
No authors listed, 1995, Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC), MMWR Recomm Rep, 44, 1
Ligova, 2009, Clostridium difficile associated diarrhoea–problem of oncological patient? [in German], Klin Onkol, 22, 108
Cloutier, 2009, Neutropenic enterocolitis, Emerg Med Clin North Am, 27, 415, 10.1016/j.emc.2009.04.002
Kang, 2005, Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome, Antimicrob Agents Chemother, 49, 760, 10.1128/AAC.49.2.760-766.2005
Ibrahim, 2000, The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting, Chest, 118, 146, 10.1378/chest.118.1.146
Lodise, 2007, Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection, Antimicrob Agents Chemother, 51, 3510, 10.1128/AAC.00338-07
Paul, 2006, Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis, Cochrane Database Syst Rev, 10.1002/14651858.CD003344.pub2
Safdar, 2004, Does combination antimicrobial therapy reduce mortality in and gram-negative bacteraemia? A meta-analysis, Lancet Infect Dis, 4, 519, 10.1016/S1473-3099(04)01108-9
No authors listed, 2005, Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia, Am J Respir Crit Care Med, 171, 388, 10.1164/rccm.200405-644ST
Kollef, 2000, Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients, Clin Infect Dis, 31, S131, 10.1086/314079
Jaksic, 2006, Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer, Clin Infect Dis, 42, 597, 10.1086/500139
Faguer, 2007, Linezolid-related pancytopenia in organ-transplant patients: report of two cases, Infection, 35, 275, 10.1007/s15010-007-6197-6
Levy, 2007, Prospective study of bacteremia and complications with EUS FNA of rectal and perirectal lesions, Clin Gastroenterol Hepatol, 5, 684, 10.1016/j.cgh.2007.02.029
Gorschluter, 2005, Neutropenic enterocolitis in adults: systematic analysis of evidence quality, Eur J Haematol, 75, 1, 10.1111/j.1600-0609.2005.00442.x
Cronin, 2009, Imaging of the gastrointestinal complications of systemic chemotherapy, Clin Radiol, 64, 724, 10.1016/j.crad.2009.02.016
Marra, 2000, A new ciprofloxacin stepdown program in the treatment of high-risk febrile neutropenia: a clinical and economic analysis, Pharmacotherapy, 20, 931, 10.1592/phco.20.11.931.35258
Hodgson-Viden, 2005, Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia, BMC Pediatr, 5, 10, 10.1186/1471-2431-5-10
Lehrnbecher, 2002, Short courses of intravenous empirical antibiotic treatment in selected febrile neutropenic children with cancer, Infection, 30, 17, 10.1007/s15010-002-2094-1
Grazziutti, 2006, Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients, Bone Marrow Transplant, 37, 403, 10.1038/sj.bmt.1705251
Molina, 2007, Reticulocyte maturation parameters are reliable early predictors of hematopoietic engraftment after allogeneic stem cell transplantation, Biol Blood Marrow Transplant, 13, 172, 10.1016/j.bbmt.2006.09.007
Pizzo, 1993, Approach to the patient with prolonged granulocytopenia, Recent Results Cancer Res, 132, 57, 10.1007/978-3-642-84899-5_5
Gill, 2010, The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy, Ann Oncol, 21, 331, 10.1093/annonc/mdp297
Horowitz, 1996, Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies, Leuk Lymphoma, 23, 159, 10.3109/10428199609054816
Bodey, 1997, The treatment of febrile neutropenia: from the Dark Ages to the present, Support Care Cancer, 5, 351, 10.1007/s005200050091
Bow, 2005, Management of the febrile neutropenic cancer patient: lessons from 40 years of study, Clin Microbiol Infect, 11, 24, 10.1111/j.1469-0691.2005.01240.x
Cruciani, 1996, Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis, Clin Infect Dis, 23, 795, 10.1093/clinids/23.4.795
Cruciani, 2003, Reappraisal with meta-analysis of the addition of gram-positive prophylaxis to fluoroquinolone in neutropenic patients, J Clin Oncol, 21, 4127, 10.1200/JCO.2003.01.234
Rotstein, 1997, Fluoroquinolone prophylaxis for profoundly neutropenic cancer patients: a meta-analysis, Opin Oncol, 4, 2
Gafter-Gvili, 2005, Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients, Ann Intern Med, 142, 979, 10.7326/0003-4819-142-12_Part_1-200506210-00008
Engels, 1998, Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis, J Clin Oncol, 16, 1179, 10.1200/JCO.1998.16.3.1179
van de Wetering, 2005, Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials, Eur J Cancer, 41, 1372, 10.1016/j.ejca.2005.03.006
Baden, 2005, Prophylactic antimicrobial agents and the importance of fitness, N Engl J Med, 353, 1052, 10.1056/NEJMe058133
van Belkum, 2005, Prophylactic application of fluoroquinolones for selective decontamination of the gut: friend or foe, Eur J Clin Microbiol Infect Dis, 24, 109, 10.1007/s10096-005-1282-1
Almyroudis, 2006, Antibacterial prophylaxis in patients with cancer and neutropenia, N Engl J Med, 354, 90, 10.1056/NEJMc052613
Pasqualotto, 2006, Antibacterial prophylaxis in patients with cancer and neutropenia, N Engl J Med, 354, 90, 10.1056/NEJMc052613
Dykewicz, 2001, Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients, Clin Infect Dis, 33, 139, 10.1086/321805
Masaoka, 2004, Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary, Clin Infect Dis, 39, S49, 10.1086/383054
Santolaya, 2005, Consensus: Rational approach towards the patient with cancer, fever and neutropenia [in Spanish], Rev Chilena Infectol, 22, S79, 10.4067/S0716-10182005000500001
Link, 2003, Antimicrobial therapy of unexplained fever in neutropenic patients–guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society), Ann Hematol, 82, S105, 10.1007/s00277-003-0764-4
Tomblyn, 2009, Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective, Biol Blood Marrow Transplant, 15, 1143, 10.1016/j.bbmt.2009.06.019
Bucaneve, 2005, Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia, N Engl J Med, 353, 977, 10.1056/NEJMoa044097
Cullen, 2005, Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas, N Engl J Med, 353, 988, 10.1056/NEJMoa050078
Leibovici, 2006, Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions, Cancer, 107, 1743, 10.1002/cncr.22205
Noel, 2007, Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders, Pediatr Infect Dis J, 26, 879, 10.1097/INF.0b013e3180cbd382
Richard, 1997, Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group, Pediatr Infect Dis J, 16, 572, 10.1097/00006454-199706000-00007
Hampel, 1997, Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use–safety report, Pediatr Infect Dis J, 16, 127, 10.1097/00006454-199701000-00036
Reuter, 2005, Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies, Clin Infect Dis, 40, 1087, 10.1086/428732
Ito, 2006, Antibacterial prophylaxis in patients with cancer and neutropenia, N Engl J Med, 354, 90, 10.1056/NEJMc052613
Kern, 2005, Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia, Eur J Clin Microbiol Infect Dis, 24, 111, 10.1007/s10096-005-1278-x
Gomez, 2003, Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin and resistant Escherichia coli, Cancer, 97, 419, 10.1002/cncr.11044
Martino, 1998, Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity, Acta Haematol, 99, 206, 10.1159/000040840
Gasink, 2006, Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact, Am J Med, 119, e19
Kaye, 2006, Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa, Antimicrob Agents Chemother, 50, 2192, 10.1128/AAC.00060-06
Muto, 2005, A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use, Infect Control Hosp Epidemiol, 26, 273, 10.1086/502539
Pepin, 2005, Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec, Clin Infect Dis, 41, 1254, 10.1086/496986
1994, Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer, AMA, 272, 1183, 10.1001/jama.1994.03520150051036
Gardner, 2008, Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia, J Clin Oncol, 26, 5684, 10.1200/JCO.2008.16.4681
Bow, 1997, Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults, J Clin Oncol, 15, 2254, 10.1200/JCO.1997.15.6.2254
Blijlevens, 2002, Impaired gut function as risk factor for invasive candidiasis in neutropenic patients, Br J Haematol, 117, 259, 10.1046/j.1365-2141.2002.03394.x
Nucci, 2001, Revisiting the source of candidemia: skin or gut?, Clin Infect Dis, 33, 1959, 10.1086/323759
Ullmann, 2007, Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease, N Engl J Med, 356, 335, 10.1056/NEJMoa061098
Kanda, 2000, Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials, Cancer, 89, 1611, 10.1002/1097-0142(20001001)89:7<1611::AID-CNCR27>3.0.CO;2-B
Playford, 2006, Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients, Eur J Clin Microbiol Infect Dis, 25, 549, 10.1007/s10096-006-0182-3
Gerson, 1984, Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia, Ann Intern Med, 100, 345, 10.7326/0003-4819-100-3-345
Portugal, 2009, Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve, J Clin Oncol, 27, 3849, 10.1200/JCO.2008.21.0856
Pagano, 2006, The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study, Haematologica, 91, 1068
de Pauw, 2006, Empiric versus preemptive therapy in the management of febrile neutropenia in the patient being treated for hematologic malignancy, Transpl Infect Dis, 8, 1, 10.1111/j.1399-3062.2006.00123.x
DeGregorio, 1982, Fungal infections in patients with acute leukemia, Am J Med, 73, 543, 10.1016/0002-9343(82)90334-5
Cornely, 2007, Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia, N Engl J Med, 356, 348, 10.1056/NEJMoa061094
Walsh, 1999, Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group, N Engl J Med, 340, 764, 10.1056/NEJM199903113401004
Walsh, 2002, Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever, N Engl J Med, 346, 225, 10.1056/NEJM200201243460403
Walsh, 2004, Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia, N Engl J Med, 351, 1391, 10.1056/NEJMoa040446
Wingard, 2000, A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group, Clin Infect Dis, 31, 1155, 10.1086/317451
Fleming, 2001, Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia, Leuk Lymphoma, 40, 511, 10.3109/10428190109097650
Boogaerts, 2001, Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial, Ann Intern Med, 135, 412, 10.7326/0003-4819-135-6-200109180-00010
Herbrecht, 2002, Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis, N Engl J Med, 347, 408, 10.1056/NEJMoa020191
Kullberg, 2005, Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial, Lancet, 366, 1435, 10.1016/S0140-6736(05)67490-9
Trifilio, 2007, Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole, Bone Marrow Transplant, 40, 451, 10.1038/sj.bmt.1705754
Krishna, 2007, Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease, Pharmacotherapy, 27, 1627, 10.1592/phco.27.12.1627
Caillot, 1997, Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery, J Clin Oncol, 15, 139, 10.1200/JCO.1997.15.1.139
Maertens, 2005, Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study, Clin Infect Dis, 41, 1242, 10.1086/496927
Hebart, 2009, A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT, Bone Marrow Transplant, 43, 553, 10.1038/bmt.2008.355
Caillot, 2001, Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia, J Clin Oncol, 19, 253, 10.1200/JCO.2001.19.1.253
Greene, 2007, Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign, Clin Infect Dis, 44, 373, 10.1086/509917
Kuhlman, 1985, Invasive pulmonary aspergillosis in acute leukemia: characteristic findings on CT, the CT halo sign, the role of CT in early diagnosis, Radiology, 157, 611, 10.1148/radiology.157.3.3864189
Greene, 2007, Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign, Clin Infect Dis, 44, 373, 10.1086/509917
Odabasi, 2004, Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome, Clin Infect Dis, 39, 199, 10.1086/421944
Ostrosky-Zeichner, 2005, Multicenter clinical evaluation of the (1–>3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans, Clin Infect Dis, 41, 654, 10.1086/432470
Senn, 2008, 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia, Clin Infect Dis, 46, 878, 10.1086/527382
Segal, 2007, Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts, Clin Infect Dis, 44, 402, 10.1086/510677
Wheat, 2007, Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay, Clin Vaccine Immunol, 14, 638, 10.1128/CVI.00479-06
Wheat, 2003, Rapid diagnosis of invasive aspergillosis by antigen detection, Transpl Infect Dis, 5, 158, 10.1111/j.1399-3062.2003.00031.x
Mennink-Kersten, 2004, Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis, Lancet Infect Dis, 4, 349, 10.1016/S1473-3099(04)01045-X
Maertens, 2002, Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients, J Infect Dis, 186, 1297, 10.1086/343804
Herbrecht, 2002, Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients, J Clin Oncol, 20, 1898, 10.1200/JCO.2002.07.004
Maertens, 2001, Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation, Blood, 97, 1604, 10.1182/blood.V97.6.1604
Sulahian, 2001, Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study, Cancer, 91, 311, 10.1002/1097-0142(20010115)91:2<311::AID-CNCR1003>3.0.CO;2-3
Pinel, 2003, Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis, J Clin Microbiol, 41, 2184, 10.1128/JCM.41.5.2184-2186.2003
Marr, 2005, Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay, Clin Infect Dis, 40, 1762, 10.1086/429921
Marr, 2004, Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance, J Infect Dis, 190, 641, 10.1086/422009
Hope, 2005, Laboratory diagnosis of invasive aspergillosis, Lancet Infect Dis, 5, 609, 10.1016/S1473-3099(05)70238-3
Pfeiffer, 2006, Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis, Clin Infect Dis, 42, 1417, 10.1086/503427
Guo, 2010, Accuracy of bronchoalveolar lavage galactomannan in diagnosing invasive aspergillosis: a bivariate meta-analysis and systematic review, Chest, 138, 817, 10.1378/chest.10-0488
Clancy, 2007, Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients, J Clin Microbiol, 45, 1759, 10.1128/JCM.00077-07
Meersseman, 2008, Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients, Am J Respir Crit Care Med, 177, 27, 10.1164/rccm.200704-606OC
Cordonnier, 2009, Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial, Clin Infect Dis, 48, 1042, 10.1086/597395
Marr, 2009, Empirical versus preemptive antifungal therapy for fever during neutropenia, Clin Infect Dis, 49, 1138, 10.1086/605601
Weisser, 2005, Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies, Clin Infect Dis, 41, 1143, 10.1086/444462
Aguilar-Guisado, 2009, Empirical antifungal therapy in selected patients with persistent febrile neutropenia, Bone Marrow Transplant, 45, 159, 10.1038/bmt.2009.125
de Pauw, 2009, Timely intervention for invasive fungal disease: should the road now lead to the laboratory instead of the pharmacy?, Clin Infect Dis, 48, 1052, 10.1086/597396
Goodman, 1992, A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation, N Engl J Med, 326, 845, 10.1056/NEJM199203263261301
Slavin, 1995, Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation–a prospective, randomized, double-blind study, J Infect Dis, 171, 1545, 10.1093/infdis/171.6.1545
Rotstein, 1999, Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group, Clin Infect Dis, 28, 331, 10.1086/515128
Bow, 2002, Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials, Cancer, 94, 3230, 10.1002/cncr.10610
Robenshtok, 2007, Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis, J Clin Oncol, 25, 5471, 10.1200/JCO.2007.12.3851
van Burik, 2004, Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation, Clin Infect Dis, 39, 1407, 10.1086/422312
Vardakas, 2005, Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials, Br J Haematol, 131, 22, 10.1111/j.1365-2141.2005.05727.x
Hachem, 2008, The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy, Cancer, 112, 2493, 10.1002/cncr.23466
Wingard, 2007, Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogenic bllod and marrow translplant (BMT) patients [abtract #163], Blood, 110, 55a, 10.1182/blood.V110.11.163.163
Marks, 2009, Voriconazole (VOR) vs itraconazole (ITR) for primary prophylaxis of invasive fungal infection (IFI) in allogeneic hematopoietic cell transplant (HCT) recipients [abstract M-1249a], Program and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy
Vehreschild, 2007, A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML), J Infect, 55, 445, 10.1016/j.jinf.2007.07.003
Mattiuzzi, 2006, Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies, Antimicrob Agents Chemother, 50, 143, 10.1128/AAC.50.1.143-147.2006
Glasmacher, 2003, Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients, J Clin Oncol, 21, 4615, 10.1200/JCO.2003.04.052
Marr, 2004, Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants, Blood, 103, 1527, 10.1182/blood-2003-08-2644
Winston, 2003, Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial, Ann Intern Med, 138, 705, 10.7326/0003-4819-138-9-200305060-00006
Lipp, 2008, Antifungal agents–clinical pharmacokinetics and drug interactions, Mycoses, 51, 7, 10.1111/j.1439-0507.2008.01523.x
Lebeaux, 2009, Therapeutic drug monitoring of posaconazole: a monocentric study in 54 adults, Antimicrob Agents Chemother, 53, 5224, 10.1128/AAC.00939-09
Thompson, 2009, Posaconazole therapeutic drug monitoring: a reference laboratory experience, Antimicrob Agents Chemother, 53, 2223, 10.1128/AAC.00240-09
Marr, 2004, Cyclophosphamide metabolism is affected by azole antifungals, Blood, 103, 1557, 10.1182/blood-2003-07-2512
Chen, 2007, Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia, Am J Hematol, 82, 942, 10.1002/ajh.20918
Mantadakis, 2007, Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia, J Pediatr Hematol Oncol, 29, 130, 10.1097/MPH.0b013e318030d289
Karp, 1988, An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis, Am J Med, 85, 203, 10.1016/S0002-9343(88)80343-7
Cordonnier, 2004, Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients, Bone Marrow Transplant, 33, 943, 10.1038/sj.bmt.1704469
Miyakis, 2009, Voriconazole concentrations and outcome of invasive fungal infections, Clin Microbiol Infect, 16, 927, 10.1111/j.1469-0691.2009.02990.x
Poirier, 1996, Marked intra- and inter-patient variability of itraconazole steady state plasma concentrations, Therapie, 51, 163
Pascual, 2008, Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes, Clin Infect Dis, 46, 201, 10.1086/524669
Marr, 2000, Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial, Blood, 96, 2055, 10.1182/blood.V96.6.2055
Trifilio, 2004, Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice, Bone Marrow Transplant, 33, 735, 10.1038/sj.bmt.1704423
Saral, 1981, Acyclovir prophylaxis of herpes-simplex-virus infections, N Engl J Med, 305, 63, 10.1056/NEJM198107093050202
Saral, 1983, Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study, Ann Intern Med, 99, 773, 10.7326/0003-4819-99-6-773
Boeckh, 2006, Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation–a randomized double-blind placebo-controlled study, Blood, 107, 1800, 10.1182/blood-2005-09-3624
Limaye, 2001, Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients, J Infect Dis, 183, 377, 10.1086/318089
Nordoy, 2002, Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae, Med Oncol, 19, 71, 10.1385/MO:19:2:71
Kunisaki, 2009, Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses, Lancet Infect Dis, 9, 493, 10.1016/S1473-3099(09)70175-6
Pollyea, 2010, Utility of influenza vaccination for oncology patients, J Clin Oncol, 28, 2481, 10.1200/JCO.2009.26.6908
Ortbals, 1977, Influenza immunization of adult patients with malignant diseases, Ann Intern Med, 87, 552, 10.7326/0003-4819-87-5-552
Robertson, 2000, Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma, Br J Cancer, 82, 1261, 10.1054/bjoc.1999.1088
Vu, 2007, Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study, Clin Infect Dis, 45, 187, 10.1086/518985
Martino, 2003, Respiratory virus infections in adults with hematologic malignancies: a prospective study, Clin Infect Dis, 36, 1, 10.1086/344899
Peck, 2007, Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection, Blood, 110, 1681, 10.1182/blood-2006-12-060343
Weinstock, 2000, Control of influenza A on a bone marrow transplant unit, Infect Control Hosp Epidemiol, 21, 730, 10.1086/501726
Chemaly, 2007, Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study, Clin Infect Dis, 44, 964, 10.1086/512374
Nichols, 2004, Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy, Clin Infect Dis, 39, 1300, 10.1086/425004
Nichols, 2001, Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome, Blood, 98, 573, 10.1182/blood.V98.3.573
Small, 2002, Respiratory syncytial virus infection following hematopoietic stem cell transplantation, Bone Marrow Transpl, 29, 321, 10.1038/sj.bmt.1703365
de Fontbrune, 2007, Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation, Clin Infect Dis, 45, 1019, 10.1086/521912
Symeonidis, 2007, Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir, Transpl Infect Dis, 9, 108, 10.1111/j.1399-3062.2006.00184.x
Kuderer, 2007, Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review, J Clin Oncol, 25, 3158, 10.1200/JCO.2006.08.8823
Pinto, 2007, Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials, Curr Med Res Opin, 23, 2283, 10.1185/030079907X219599
Aapro, 2006, EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours, Eur J Cancer, 42, 2433, 10.1016/j.ejca.2006.05.002
Smith, 2006, 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline, J Clin Oncol, 24, 3187, 10.1200/JCO.2006.06.4451
National Cancer Center Network (NCCN), 2009, Myeloid growth factors: NCCN practice guidelines
Timmer-Bonte, 2006, Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer, J Clin Oncol, 24, 2991, 10.1200/JCO.2005.04.3281
Timmer-Bonte, 2008, Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy, J Clin Oncol, 26, 290, 10.1200/JCO.2007.13.0898
Adams, 2006, When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?, J Clin Oncol, 24, 2975, 10.1200/JCO.2006.05.6812
Kuderer, 2006, Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients, Cancer, 106, 2258, 10.1002/cncr.21847
Wingard, 2009, Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics, Crit Rev Oncol Hematol, 72, 144, 10.1016/j.critrevonc.2009.01.003
Lyman, 2007, Granulocyte colony-stimulating factors: finding the right indication, Curr Opin Oncol, 19, 299, 10.1097/CCO.0b013e3281a3c0ba
Maher, 1994, Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial, Ann Intern Med, 121, 492, 10.7326/0003-4819-121-7-199410010-00004
Vellenga, 1996, Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia, J Clin Oncol, 14, 619, 10.1200/JCO.1996.14.2.619
Garcia-Carbonero, 2001, Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial, J Natl Cancer Inst, 93, 31, 10.1093/jnci/93.1.31
Clark, 2005, Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials, J Clin Oncol, 23, 4198, 10.1200/JCO.2005.05.645
Raad, 2004, Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections, Ann Intern Med, 140, 18, 10.7326/0003-4819-140-1-200401060-00007
Maki, 2006, The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies, Mayo Clin Proc, 81, 1159, 10.4065/81.9.1159
Raad, 1993, Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement, J Infect Dis, 168, 400, 10.1093/infdis/168.2.400
Mermel, 2009, Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America, Clin Infect Dis, 49, 1, 10.1086/599376
Seifert, 2003, Bloodstream infection in neutropenic cancer patients related to short-term nontunnelled catheters determined by quantitative blood cultures, differential time to positivity, and molecular epidemiological typing with pulsed-field gel electrophoresis, J Clin Microbiol, 41, 118, 10.1128/JCM.41.1.118-123.2003
Chatzinikolaou, 2004, Differential quantitative blood cultures for the diagnosis of catheter-related bloodstream infections associated with short- and long-term catheters: a prospective study, Diagn Microbiol Infect Dis, 50, 167, 10.1016/j.diagmicrobio.2004.07.007
Douard, 1994, Negative catheter-tip culture and diagnosis of catheter-related bacteremia, Nutrition, 10, 397
Capdevila, 1992, Value of differential quantitative blood cultures in the diagnosis of catheter-related sepsis, Eur J Clin Microbiol Infect Dis, 11, 403, 10.1007/BF01961854
Douard, 1999, Diagnosis of venous access port-related infections, Clin Infect Dis, 29, 1197, 10.1086/313444
Flynn, 1988, Differential quantitation with a commercial blood culture tube for diagnosis of catheter-related infection, J Clin Microbiol, 26, 1045, 10.1128/JCM.26.5.1045-1046.1988
Raucher, 1984, Quantitative blood cultures in the evaluation of septicemia in children with Broviac catheters, J Pediatr, 104, 29, 10.1016/S0022-3476(84)80584-3
Safdar, 2005, Meta-analysis: methods for diagnosing intravascular device-related bloodstream infection, Ann Intern Med, 142, 451, 10.7326/0003-4819-142-6-200503150-00011
Blot, 1998, Earlier positivity of central-venous- versus peripheral-blood cultures is highly predictive of catheter-related sepsis, J Clin Microbiol, 36, 105, 10.1128/JCM.36.1.105-109.1998
Blot, 1999, Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures, Lancet, 354, 1071, 10.1016/S0140-6736(98)11134-0
Fowler, 1998, Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients, Clin Infect Dis, 27, 478, 10.1086/514686
Dugdale, 1990, Staphylococcus aureus bacteremia in patients with Hickman catheters, Am J Med, 89, 137, 10.1016/0002-9343(90)90290-T
Hanna, 2004, Central venous catheter-related bacteremia due to gram-negative bacilli: significance of catheter removal in preventing relapse, Infect Control Hosp Epidemiol, 25, 646, 10.1086/502455
Nguyen, 1995, Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study, Arch Intern Med, 155, 2429, 10.1001/archinte.1995.00430220087009
Raad, 2004, Management of central venous catheters in patients with cancer and candidemia, Clin Infect Dis, 38, 1119, 10.1086/382874
Benoit, 1995, Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home, Clin Infect Dis, 21, 1286, 10.1093/clinids/21.5.1286
Johnson, 1994, Preliminary results treating persistent central venous catheter infections with the antibiotic lock technique in pediatric patients, Pediatr Infect Dis J, 13, 930, 10.1097/00006454-199410000-00015
Krzywda, 1995, Treatment of Hickman catheter sepsis using antibiotic lock technique, Infect Control Hosp Epidemiol, 16, 596, 10.2307/30141101
Messing, 1988, Antibiotic-lock technique: a new approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients, JPEN J Parenter Enteral Nutr, 12, 185, 10.1177/0148607188012002185
Raad, 1997, Minocycline and ethylenediaminetetraacetate for the prevention of recurrent vascular catheter infections, Clin Infect Dis, 25, 149, 10.1086/514518
Ghanem, 2007, Catheter-related Staphylococcus aureus bacteremia in cancer patients: high rate of complications with therapeutic implications, Medicine (Baltimore), 86, 54, 10.1097/MD.0b013e318030d344
Raad, 1994, Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion, Infect Control Hosp Epidemiol, 15, 231, 10.2307/30145574
Boyce, 2002, Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America, MMWR Recomm Rep, 51, 1
Siegel, 2007, 2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings, Am J Infect Control, 35, S65, 10.1016/j.ajic.2007.10.007
2000, Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients, MMWR Recomm Rep, 49, 1
1997, Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC), MMWR Recomm Rep, 46, 1
Yokoe, 2008, A compendium of strategies to prevent healthcare-associated infections in acute care hospitals, Infect Control Hosp Epidemiol, 29, S12, 10.1086/591060
National Comprehensive Cancer Network (NCCN), 2009